Rapid Health Technology Assessment on Niaoduqing Granules in the Treatment of Chronic Kidney Disease
OBJECTIVE:To evaluate the efficacy,safety and economical efficiency of Niaoduqing granules in the treatment of chronic kidney disease(CKD)by rapid health technology assessment(HTA),so as to provide evidence-based evidence for clinic.METHODS:HTA reports,systematic reviews,Meta-analysis and pharmacoeconomics researches related to Niaoduqing granules for the treatment of CKD were enrolled by retrieving PubMed,the Cochrane Library,CBM,CNKI,Wanfang Data and VIP databases(search deadline until Feb.1st,2024),the quality of enrolled studies was evaluated and the results were qualitatively analyzed.RESULTS:A total of 13 Meta-analysis were enrolled,no HTA reports or pharmacoeconomics researches were retrieved.The results indicated that the clinical effective rate of the combined application of Niaoduqing granules for the treatment of CKD was better than other therapeutic regimens(the results of studies with the highest number of cases showed that RR=1.37,95%CI=1.24-1.51,P<0.001),and it could promote the endogenous creatinine clearance rate,glomerular filtration rate,hemoglobin level,which also had advantages in reducing serum creatinine,serum urea nitrogen,urinary albumin excretion rate,24 h urine protein,serum total cholesterol,serum triacylglycerol and cystatin C levels,with good safety and low incidence of adverse drug reactions.CONCLUSIONS:The combined application of Niaoduqing granules has good efficacy and safety in the treatment of CKD.It is necessary to further perform pharmacoeconomic research to supplement the economic evaluation evidence for the treatment of CKD.
Niaoduqing granulesChronic kidney diseaseEffectivenessSafetyEconomical efficiencyRapid health technology assessment
国家科技期刊平台
NSTL
万方数据
